Day One Bio­phar­ma­ceu­ti­cals inks re­search col­lab­o­ra­tion with Swedish biotech

Day One Bio­phar­ma­ceu­ti­cals se­cured a re­search and li­cens­ing deal with Sprint Bio­science in a bid to build out its can­cer-fight­ing ar­se­nal.

The Bay Area biotech is pay­ing $3 mil­lion up­front for the glob­al rights of one of Sprint’s can­cer pro­grams known as VA­DA, which is de­signed to tar­get the pro­tein known as vac­cinia-re­lat­ed ki­nase 1 or VRK1, which is preva­lent in kid­ney, liv­er and pan­cre­at­ic can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER